Work

Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM)

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.3591

Authors: L. Cripe, W. McGuire, M. Wertheim, P. Eisenberg, W. Stadler, R. Paquette, T. Logan, T. Zimmerman, D. Matei, U. Matulonis

Institutions: University of California, Los Angeles, University of Chicago, Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2284996855

Cites:

Cited by: 9

Related to: 10